The landscape of Alzheimer’s disease diagnosis has shifted dramatically. In May 2025, the FDA cleared the first blood test to help identify Alzheimer’s disease—a watershed moment that fundamentally expands access to diagnostic testing beyond expensive, specialized imaging centers. This blood test measures two proteins with over 91% agreement with brain scans, and just months later in October 2025, the FDA cleared a second blood-based option, Roche’s Elecsys test, specifically for use in primary care settings. The expansion doesn’t stop there: updated clinical practice guidelines, improved portable imaging technology, and expanded Medicare reimbursement policies have created a convergence of innovations that bring Alzheimer’s diagnosis within reach of more patients and primary care doctors than ever before.
This article explores how these advances are reshaping diagnostics, what it means for patients in rural areas and underserved communities, and what barriers still remain. Access to Alzheimer’s diagnosis has traditionally been a privilege of patients near major medical centers with PET imaging capabilities and specialists. A single PET scan for Alzheimer’s assessment costs Medicare over $4,700, while blood-based biomarker tests reimburse at approximately $130—a 36-fold cost difference. For patients in rural areas where specialty imaging may require travel of hours or days, this gap has meant many never receive a definitive diagnosis. The new blood tests and updated clinical guidelines are narrowing that gap, but understanding how these tools work and when they apply is critical for patients and their families navigating diagnostic decisions.
Table of Contents
- What Changed With Blood-Based Biomarker Tests for Alzheimer’s?
- How Blood Tests Compare to Traditional PET Imaging—And When Each Applies
- Medicare Coverage Expansion Opening Doors for Seniors
- Portable MRI Technology Expanding Imaging Options Beyond Traditional Centers
- Updated Clinical Guidelines Reshaping Diagnostic Practice
- Real-World Data From the ALZ-NET Registry
- Looking Forward—What Expansion Means for Future Diagnosis
- Conclusion
What Changed With Blood-Based Biomarker Tests for Alzheimer’s?
Blood-based biomarker testing represents a fundamental shift in how doctors can assess brain changes associated with Alzheimer’s disease. For decades, diagnosis relied almost entirely on cognitive testing combined with PET imaging or cerebrospinal fluid analysis—both requiring specialized equipment or procedures. The FDA-cleared blood tests measure specific proteins like phosphorylated tau and amyloid-beta that appear in the bloodstream when these pathological changes occur in the brain, offering an indirect but increasingly reliable window into what’s happening in neural tissue. The clinical significance is substantial: these blood tests show greater than 91% agreement with findings on PET brain imaging, meaning they’re catching the same underlying pathology that imaging would reveal.
For a patient experiencing memory concerns, this means their primary care doctor can now order a simple blood test during a routine office visit—no waiting for an imaging appointment, no radiation exposure, no travel to a specialty center. A 75-year-old with early memory loss in a rural Montana town can get answers from their local physician, rather than facing a 200-mile drive to the nearest PET center. However, blood tests are not a replacement for all imaging—they’re specifically tools to assess for amyloid and tau pathology. A normal blood test doesn’t rule out other causes of cognitive impairment like stroke, subdural hematoma, or normal pressure hydrocephalus, which do require imaging to visualize. This is why the updated clinical guidelines emphasize blood tests as a triage tool: they help determine whether amyloid-tau pathology is present, and if so, more comprehensive evaluation may be warranted.
How Blood Tests Compare to Traditional PET Imaging—And When Each Applies
The comparison between blood-based testing and PET imaging reveals important tradeoffs. PET imaging provides spatial information—clinicians can see exactly where amyloid or tau accumulation occurs in the brain, information that matters for some research studies and specialized clinical questions. Blood tests provide only a yes-no answer about whether the pathology is present systemically. For most patients simply seeking to understand whether their memory problems stem from Alzheimer’s pathology, this suffices. For researchers studying how pathology distribution correlates with specific cognitive deficits, PET remains necessary. Cost creates another crucial distinction.
A patient with concerns about cognitive decline facing a $4,700 PET imaging bill out-of-pocket might postpone or avoid testing altogether. The same patient can afford a $130 blood test covered by Medicare or insurance as a routine office lab. This accessibility difference has profound implications: studies show that cost barriers are among the strongest predictors of whether patients with cognitive concerns actually receive diagnostic evaluation. Reducing cost from $4,700 to $130 transforms the economics of diagnosis. However, if a patient has already been referred to a specialist or has complex diagnostic uncertainty—such as distinguishing between Alzheimer’s pathology and Lewy body disease—targeted PET imaging may still provide essential additional information. The 2025 updated appropriate use criteria from the Alzheimer’s Association and Society for Nuclear Medicine now explicitly rates different clinical scenarios as “appropriate,” “uncertain,” or “rarely appropriate” for PET imaging, creating a framework where blood tests handle most initial screening while PET focuses on complex cases.
Medicare Coverage Expansion Opening Doors for Seniors
The reimbursement landscape for Alzheimer’s diagnostics underwent significant changes between 2023 and 2024 that directly increased access. In 2023, the Centers for Medicare & Medicaid Services lifted the previous restriction limiting patients to one PET scan per lifetime for amyloid and tau assessment. That same year, CMS expanded coverage for blood-based biomarker tests. Then in 2024, CMS unbundled payment for high-cost diagnostic radiopharmaceuticals used in PET imaging, meaning hospitals and imaging centers could access better reimbursement for these scans, removing financial disincentives to offer them. For a Medicare beneficiary, these changes mean their Part B coverage now extends to initial diagnostic blood testing through their primary care doctor, with straightforward reimbursement.
An 82-year-old with concerns about memory loss can ask their internist about testing, which the doctor can order without insurance pre-authorization hurdles that might have delayed testing previously. The combination of lower out-of-pocket costs for blood tests and improved PET reimbursement created redundancy in the system—most patients can access diagnosis through blood testing, while those needing specialized imaging have better pathways to it. Yet this expansion hasn’t automatically solved access disparities. Rural Medicare beneficiaries still face barriers if their primary care doctor is unfamiliar with newer blood tests or uncertain how to interpret results. A clinic in a county with no neurologist nearby might order the test but lack confidence in managing the findings—something the field is addressing through updated clinical education and clearer practice guidelines.
Portable MRI Technology Expanding Imaging Options Beyond Traditional Centers
While blood tests and updated PET guidelines are reshaping how diagnosis begins, a parallel innovation is expanding imaging accessibility through low-field MRI technology. Traditional MRI machines use very strong magnetic fields (typically 1.5 to 3 Tesla), require dedicated imaging suites with specialized infrastructure, and cost millions of dollars. Low-field MRI systems operate at magnetic field strengths 50 times weaker than conventional machines, yet combined with advanced machine learning algorithms, they can accurately measure brain characteristics relevant to Alzheimer’s disease—including brain atrophy patterns and white matter changes. This technology matters for access because low-field MRI machines are smaller, less expensive to install, and can function in settings where high-field imaging isn’t feasible. Some institutions are now exploring portable or semi-portable systems that could be deployed to rural clinics, rural hospitals, or mobile health units.
Research from Mass General Brigham demonstrated that low-field MRI with machine learning reaches comparable accuracy to conventional MRI for measuring brain structures relevant to Alzheimer’s assessment—a breakthrough that could enable diagnostic imaging in communities that currently have none. The limitation remains that low-field MRI hasn’t yet replaced conventional MRI or PET across all diagnostic scenarios. It excels at measuring brain structure and volume but doesn’t visualize amyloid-tau pathology the way PET does. The emerging role is likely complementary: blood tests identify patients with amyloid-tau pathology, and low-field MRI might assess brain atrophy or structural changes in more accessible settings. However, patients needing visualization of specific pathological distributions would still require conventional PET imaging.
Updated Clinical Guidelines Reshaping Diagnostic Practice
In January 2025, the Alzheimer’s Association and Society for Nuclear Medicine and Molecular Imaging released the first major update to appropriate use criteria for amyloid and tau PET imaging since 2013. These guidelines essentially codify when PET imaging is worthwhile and when blood tests or other approaches are preferred. The updated criteria cover 17 distinct clinical scenarios rated as “appropriate,” “uncertain,” or “rarely appropriate” for PET use. This framework represents a significant shift from “do imaging on everyone with memory concerns” to “match the test to the clinical question.” For example, PET imaging is rated “appropriate” for patients with documented cognitive impairment where amyloid-tau status would change management (such as considering amyloid-targeting medications). For patients with subjective concerns about memory but normal cognitive testing, blood tests are typically the starting point, with PET reserved for cases where blood testing is inconclusive or results don’t align with clinical picture.
For patients with clearly non-Alzheimer’s cognitive impairment, PET is rarely appropriate. However, implementing these nuanced guidelines requires clinician education and shift in diagnostic culture. Many neurologists and internists remain more familiar with previous practice patterns than the 2025 criteria. Some centers have been slow to adopt blood testing pathways even though guidelines now recommend them. The gap between published guidelines and real-world practice remains a barrier—patients at some centers still face unnecessary PET imaging, while those at other centers might miss imaging that would be appropriate for their situation.
Real-World Data From the ALZ-NET Registry
Beyond clinical trials and academic studies, the ALZ-NET (Alzheimer’s Network for Treatment and Diagnostics) registry now provides real-world evidence about how newer Alzheimer’s diagnostic and treatment approaches are being deployed. This registry includes over 3,600 enrolled patients across 118 active clinical sites and captures data from patients who received FDA-approved Alzheimer’s disease-modifying treatments starting in 2021—lecanemab, aducanumab, and others that specifically target amyloid pathology.
The registry reveals which diagnostic pathways led to treatment eligibility, how blood-based testing is being integrated into practice, and what outcomes patients achieve with earlier diagnosis through these expanded programs. This real-world data provides insights that randomized trials don’t capture: How long does it actually take a patient to navigate from symptom recognition to diagnosis in contemporary practice? What percentage of patients with positive biomarkers ultimately receive disease-modifying treatment? Where do access barriers persist? These answers directly inform whether expanded diagnostic programs are truly reaching patients or simply increasing testing without improving outcomes.
Looking Forward—What Expansion Means for Future Diagnosis
The convergence of blood-based testing, updated clinical guidelines, Medicare coverage changes, and portable imaging technology represents a fundamental transformation in Alzheimer’s diagnostics, but the work is incomplete. The next phase involves integrating these tools effectively into primary care, ensuring rural and underserved communities actually benefit from the innovations, and training clinicians in blood test interpretation and guideline-concordant practice.
Future developments likely include even more accessible blood tests (perhaps finger-stick or home-based options), broader validation of low-field MRI, and progression toward earlier detection of preclinical pathology—identifying people with amyloid-tau changes before symptoms emerge. These advances create both opportunity and challenge: identifying asymptomatic people with pathology creates questions about when and whether to intervene, what information people want to know about future risk, and how healthcare systems should counsel people who test positive. The expansion of diagnostic access is reshaping not just how we identify Alzheimer’s disease, but what comes after diagnosis—an equally important frontier.
Conclusion
Brain scan programs and diagnostics for Alzheimer’s disease have expanded through complementary innovations: blood tests now offer sensitive, accessible, and affordable screening; updated clinical guidelines clarify when specialized imaging is needed; Medicare coverage changes have removed financial barriers; and portable imaging technology is bringing diagnostic capability to underserved areas. For the first time, a patient with cognitive concerns can pursue diagnosis without traveling to a major medical center, without exposure to radiation, and without expenses that might discourage testing. These advances matter most if they actually reach the patients who need them.
Implementation gaps remain—clinician familiarity with new guidelines, disparities in access based on geography and resources, and questions about what happens after diagnosis. Patients and families navigating cognitive concerns should ask their primary care doctor about blood-based biomarker testing as an initial step, understand that positive results may warrant specialist evaluation, and recognize that diagnostic expansion creates opportunities for earlier intervention with newer disease-modifying treatments. The tools have changed; now the broader healthcare system must catch up.
